125 Results for "

b+d+n+f

" in MedChemExpress (MCE) Product Catalog:
Products (125)

125 Results for "b+d+n+f" in MCE Product Catalog:

39
39 Publications Verification
Cat. No.: HY-12497
CAS No.: 219766-25-3
Purity:  99.90%
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-P1731C
Synonyms: LY3298176 sodium
Tirzepatide sodium (LY3298176 sodium) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide sodium exerts anti-apoptotic and pro-differentiation effects via the pAkt/CREB/BDNF cascade and miRNA in neurons; in the heart, it promotes BCAA catabolism and inhibits the mTOR pathway by mediating the dephosphorylation of BCKDHA; meanwhile, it effectively reduces insulin and leptin levels and suppresses inflammatory responses at the systemic level. Tirzepatide sodium can be used for research on myocardial infarction, colon cancer, diabetes, diabetic cognitive impairment, neurodegeneration, diabetes-related neuropathy, and obesity .
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-W013372
CAS No.: 38183-03-8
7,8-Dihydroxyflavone is a potent and selective TrkB agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-P7116A
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: BDNF; Abrineurin; Brain Derived Neurotrophic Factor; Brain-Derived Neurotrophic Factor Preproprotein Isoform 2; ProBDNF; Brain-Derived Neurotrophic Factor Isoform 1; Neurotrophic Factor BDNF Precursor Form; ANON2; Brain-Derived Neurotrophic Factor; BULN2
Species:  
Mouse;Rat;Human
Source:  
E. coli
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-15136
CAS No.: 193275-84-2
Purity:  99.60%
Synonyms: Sch66336
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1178
CAS No.: 1203586-72-4
Target:  

Trk Receptor p38 MAPK

Research Areas:  

Neurological Disease

Cyclotraxin B is a BBB-penetrable and selective TrkB inhibitor. Cyclotraxin B inhibits BDNF-induced TrkB activity in a non-competitive manner, with an IC50 of 0.30 nM. Cyclotraxin B has analgesic and anxiolytic effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18939
CAS No.: 36396-99-3
Synonyms: CHA
N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P74383
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: BDNF; Abrineurin; Brain Derived Neurotrophic Factor; Brain-Derived Neurotrophic Factor Preproprotein Isoform 2; ProBDNF; Brain-Derived Neurotrophic Factor Isoform 1; Neurotrophic Factor BDNF Precursor Form; ANON2; Brain-Derived Neurotrophic Factor; BULN2
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7981
CAS No.: 2284-31-3
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153383
CAS No.: 494763-64-3
Purity:  99.65%
Research Areas:  

Cancer

PDCD4-IN-1(compound 20031600) is a PDCD4 inhibitor with a Kd value of 350 nM, which can promote the expression of BDNF in hippocampal neuron cell HT-22 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N1414A
CAS No.: 76656-80-9
3′,6-Disinapoylsucrose is a type of oligosaccharide that's effective when taken orally, and it has antidepressant, anti-anxiety, and antioxidant properties. 3′,6-Disinapoylsucrose inhibits neuronal apoptosis by lowering the ratio of Bax to Bcl-2 in hippocampal neurons, and it enhances cognitive function in APP/PS1 transgenic mice by activating the CREB/BDNF signaling pathway .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-14569
CAS No.: 781652-57-1
Purity:  99.32%
CDPPB is a selective, orally active and brain-penetrant mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16728
CAS No.: 117928-94-6
Synonyms: GLYX-13
Target:  

iGluR ERK mTOR

Research Areas:  

Neurological Disease Cancer

Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16728B
CAS No.: 1435786-04-1
Synonyms: GLYX-13 Trifluoroacetate
Target:  

iGluR mTOR ERK

Research Areas:  

Neurological Disease

Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-110255
CAS No.: 934282-55-0
Purity:  99.8%
Research Areas:  

Neurological Disease

AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P700158AF
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: BDNF; Abrineurin; Brain Derived Neurotrophic Factor; Brain-Derived Neurotrophic Factor Preproprotein Isoform 2; ProBDNF; Brain-Derived Neurotrophic Factor Isoform 1; Neurotrophic Factor BDNF Precursor Form; ANON2; Brain-Derived Neurotrophic Factor; BULN2
Species:  
Rat;Mouse;Human
Source:  
E. coli
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80567
Synonyms: BDNF; MGC34632; Abrineurin; ANON2; Brain Derived Neurotrophic Factor; Neurotrophin; BULN2

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2736
CAS No.: 2150-11-0
3′,4′,7-Trihydroxyflavone is an orally active inhibitor of OXA-48 (IC50 = 1.89 μM) and COX-1 (IC50 = 36.37 μM). 3′,4′,7-Trihydroxyflavone exhibits antioxidant and anti-inflammatory properties, inhibiting the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α. 3′,4′,7-Trihydroxyflavone inhibits H2O2-induced neuronal apoptosis and ROS accumulation, and exerts anti-neuroinflammatory effects by suppressing the JNK-STAT1 pathway. 3′,4′,7-Trihydroxyflavone exhibits antimicrobial and antibiotic-modifying activities against multidrug-resistant Gram-negative enteric bacteria. 3′,4′,7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1. 3′,4′,7-Trihydroxyflavone activates the CREB-BDNF axis and restores scopolamine (HY-N0296)-induced memory deficits in mice .
loading...
    loading...
Cat. No.: HY-124591
CAS No.: 1381769-23-8
Purity:  98.73%
Research Areas:  

Neurological Disease

TC-2153 is a selective inhibitor of striatal-enriched protein tyrosine phosphatase (STEP), with psychotropic activity and low acute toxicity. TC-2153 increases the expression of brain-derived neurotropic factor (BDNF) in the brain. And it decreases MAOA and 5-HT1A receptors mRNA level in midbrain. TC-2153 also inhibits 5-HT2A receptor-mediated signaling .
loading...
    loading...
Cat. No.: HY-N2055
CAS No.: 19895-95-5
Kaempferol 3-O-sophoroside is an orally active derivative of Kaempferol. It exhibits anti-inflammatory, analgesic, and antidepressant effects. Kaempferol 3-O-sophoroside is an inhibitor of the cell surface receptor toll-like receptor (TLR) 2/4 for High mobility group box 1 (HMGB1), and it also exerts anti-inflammatory effects by blocking the activation of NF-κB expression and the production of TNF-α. Kaempferol 3-O-sophoroside promotes the production of brain-derived neurotrophic factor (BDNF) and enhances autophagy by binding to AMP-activated protein kinase (AMPK), thereby exerting antidepressant effects. Kaempferol 3-O-sophoroside holds promise for research in the fields of inflammation and neurodegenerative diseases .
loading...
    loading...